Bristol-Myers' Opdivo extends survival in head and neck cancer -study

April 19 (Reuters) - Bristol-Myers Squibb's cancer

immunotherapy drug, Opdivo, helped advanced head and neck cancer

patients with a dismal prognosis live longer than other standard

treatments,...

Read more